Skip to main content
. Author manuscript; available in PMC: 2010 Mar 1.
Published in final edited form as: Cancer Res. 2009 Feb 24;69(5):1985–1994. doi: 10.1158/0008-5472.CAN-08-3934

Figure 2. Biological effects of the ‘Bad-like’ BH3 mimetic ABT-737 and Bad RNAi in melanoma cells.

Figure 2

(A) Apoptotic sensitivity of melanoma cell lines to ABT-737 alone and in combination with the MEK inhibitor PD98059. Cells were treated in triplicate with either the inactive enantiomer, 2.5 μM ABT-737, DMSO, or 20 μM of the MEK inhibitor PD98059 (added every 24 h) for 72 h. Apoptosis (% sub G1 fraction) was determined by cell cycle analysis using flow cytometry. Data was normalized to the control and expressed as the mean ± standard error. (B) Analysis of the requirement of the BH3-only protein Bad in CI-1040 induced apoptosis in M14-MEL and MALME-3M cell lines. Cells were treated with DMSO or 2 μM CI-1040 48 h after transfection for a duration of 72 h (120 h post-transfection). The arrow indicates the start of CI-1040 treatment. Apoptosis was determined as described in (A). Data was normalized to the control and expressed as the mean − SEM. Untransfected (◇), siCtrl (○), siBad (▲). Immunoblots demonstrate reduced expression of Bad following transfection of siRNA SMARTpool oligonucleotides targeting Bad (Dharmacon).